

## Author index

- Aas, P., see Myhrer, T. (483) 271  
 Aimi, N., see Ogura, J. (483) 139  
 Alexandre Ribeiro, J., see Illes, P. (483) 5  
 Altar, C.A., see Jordan, S. (483) 45  
 Ando, H., Fukuda, N., Kotani, M., Yokoyama, S.-i., Kunimoto, S., Matsumoto, K., Saito, S., Kanmatsuse, K. and Mugishima, H. Chimeric DNA–RNA hammerhead ribozyme targeting transforming growth factor- $\beta$ 1 mRNA inhibits neointima formation in rat carotid artery after balloon injury (483) 207  
 Assem, E.-S.K., see Narenjkar, J. (483) 95  
 Assem, E.-S.K., see Narenjkar, J. (483) 107  
  
 Bae, Y.M., see Kim, A. (483) 117  
 Bartholini, F., see Marchese, G. (483) 65  
 Bartoli, F., see Magnarin, M. (483) 19  
 Basta-Kaim, A., see Kubera, M. (483) 309  
 Bíró, T., see Maksay, G. (483) 229  
 Bot, G., see Chen, C. (483) 175  
 Buesing, W.R., see Norman, A.B. (483) 281  
  
 Cabré, F., see Díaz-Reval, M.I. (483) 241  
 Candussio, L., see Magnarin, M. (483) 19  
 Cao, C., see Piao, F.L. (483) 295  
 Caputi, A.P., see Cuzzocrea, S. (483) 79  
 Casti, P., see Marchese, G. (483) 65  
 Casu, G.L., see Marchese, G. (483) 65  
 Chan, F.L., see Tsang, S.Y. (483) 155  
 Chan, P., see Chen, Y.-C. (483) 215  
 Chang, F.-R., see Wu, C.-C. (483) 187  
 Chatterjee, P.K., see Cuzzocrea, S. (483) 79  
 Chen, C., Li, J., Bot, G., Szabo, I., Rogers, T.J. and Liu-Chen, L.-Y. Heterodimerization and cross-desensitization between the  $\mu$ -opioid receptor and the chemokine CCR5 receptor (483) 175  
 Chen, S.-A., see Chen, Y.-C. (483) 215  
 Chen, Y.-C., Chen, S.-A., Chen, Y.-J., Tai, C.-T., Chan, P. and Lin, C.-I. Effect of ethanol on the electrophysiological characteristics of pulmonary vein cardiomyocytes (483) 215  
 Chen, Y.-J., see Chen, Y.-C. (483) 215  
 Chen, Z.-Y., see Tsang, S.Y. (483) 155  
 Cho, S.I., see Kim, A. (483) 117  
 Choi, W., see Scott, V.E. (483) 195  
 Contreras, E., see Sepúlveda, J. (483) 249  
 Croci, N., see Paucard, A. (483) 259  
 Cuzzocrea, S., Pisano, B., Dugo, L., Ianaro, A., Maffia, P., Patel, N.S.A., Di Paola, R., Ialenti, A., Genovese, T., Chatterjee, P.K., Di Rosa, M., Caputi, A.P. and Thiemermann, C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor- $\gamma$ , reduces acute inflammation (483) 79  
  
 Da Motta, P.G., Veiga, A.P.C., Francischi, J.N. and Tatsuo, M.A.K.F. Evidence for participation of GABA<sub>A</sub> receptors in a rat model of secondary hyperalgesia (483) 233  
  
 Davis-Taber, R.A., see Scott, V.E. (483) 195  
 De Vry, J., Schreiber, R., Eckel, G. and Jentzsch, K.R. Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A (483) 55  
 Déciga-Campos, M., see Díaz-Reval, M.I. (483) 241  
 Decorti, G., see Magnarin, M. (483) 19  
 Díaz-Reval, M.I., Ventura-Martínez, R., Déciga-Campos, M., Terrón, J.A., Cabré, F. and López-Muñoz, F.J. Evidence for a central mechanism of action of *S*-(+)-ketoprofen (483) 241  
 Di Paola, R., see Cuzzocrea, S. (483) 79  
 Di Rosa, M., see Cuzzocrea, S. (483) 79  
 Dickenson, J.M., see Ruffels, J. (483) 163  
 Dugo, L., see Cuzzocrea, S. (483) 79  
 Dunn, R., see Jordan, S. (483) 45  
  
 Earm, Y.E., see Kim, A. (483) 117  
 Eckel, G., see De Vry, J. (483) 55  
 Endou, H., see Takeda, M. (483) 133  
 Enger, S., see Myhrer, T. (483) 271  
  
 Filip, M., see Kubera, M. (483) 309  
 France, C.P., see Sevak, R.J. (483) 289  
 Francischi, J.N., see da Motta, P.G. (483) 233  
 Friedmann, T., see Spetea, M. (483) 301  
 Fukuda, N., see Ando, H. (483) 207  
 Fürst, S., see Spetea, M. (483) 301  
  
 Ganellin, C.R., see Narenjkar, J. (483) 107  
 Genovese, T., see Cuzzocrea, S. (483) 79  
 Gerstmann, H., see Giordano, J. (483) 267  
 Giordano, J. and Gerstmann, H. Patterns of serotonin- and 2-methylserotonin-induced pain may reflect 5-HT<sub>3</sub> receptor sensitization (483) 267  
 Giraldi, T., see Magnarin, M. (483) 19  
 Gjoni, T., see Urwyler, S. (483) 147  
 Gopalakrishnan, M., see Scott, V.E. (483) 195  
 Gosens, R., Schaafsma, D., Meurs, H., Zaagsma, J. and Nelemans, S.A. Role of Rho-kinase in maintaining airway smooth muscle contractile phenotype (483) 71  
 Griffin, M., see Ruffels, J. (483) 163  
  
 Han, J.H., see Piao, F.L. (483) 295  
 Hasannejad, H., see Takeda, M. (483) 133  
 Hatanaka, K.-i., see Kimura, Y. (483) 37  
 Ho, W.-K., see Kim, A. (483) 117  
 Holan, V., see Kubera, M. (483) 309  
 Hoogenboom, L., see Scott, V.E. (483) 195  
 Horie, S., see Ogura, J. (483) 139  
 Huang, X.-L., see Takeda, M. (483) 133  
 Huang, Y., see Tsang, S.Y. (483) 155

- Ialenti, A., see Cuzzocrea, S. (483) 79
- Ianaro, A., see Cuzzocrea, S. (483) 79
- Illes, P. and Alexandre Ribeiro, J.  
Molecular physiology of P2 receptors in the central nervous system (483) 5
- Ishii-Nozawa, R., see Nakazawa, K. (483) 29
- Jentsch, K.R., see De Vry, J. (483) 55
- Jordan, S., Koprivica, V., Dunn, R., Tottori, K., Kikuchi, T. and Altar, C.A.  
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function (483) 45
- Kanmatsuse, K., see Ando, H. (483) 207
- Kaupmann, K., see Urwyler, S. (483) 147
- Khropov, Y.V., see Severina, I.S. (483) 127
- Kikuchi, T., see Jordan, S. (483) 45
- Kim, A., Bae, Y.M., Kim, J., Kim, B., Ho, W.-K., Earm, Y.E. and Cho, S.I.  
Direct block by bisindolylmaleimide of the voltage-dependent K<sup>+</sup> currents of rat mesenteric arterial smooth muscle (483) 117
- Kim, B., see Kim, A. (483) 117
- Kim, J., see Kim, A. (483) 117
- Kim, S.H., see Piao, F.L. (483) 295
- Kim, S.Z., see Piao, F.L. (483) 295
- Kimura, Y., Hatanaka, K.-i., Naitou, Y., Maeno, K., Shimada, I., Koakutsu, A., Wanibuchi, F. and Yamaguchi, T.  
Pharmacological profile of YM348, a novel, potent and orally active 5-HT<sub>2C</sub> receptor agonist (483) 37
- Kiss, B., see Maksay, G. (483) 229
- Ko, Y.D., see Neuhaus, T. (483) 223
- Koakutsu, A., see Kimura, Y. (483) 37
- Koek, W., see Sevak, R.J. (483) 289
- Koprivica, V., see Jordan, S. (483) 45
- Kotani, M., see Ando, H. (483) 207
- Kroeger, P., see Scott, V.E. (483) 195
- Kubera, M., Filip, M., Basta-Kaim, A., Nowak, E., Siwanowicz, J., Zajicova, A., Holan, V., Maes, M. and Lasoń, W.  
The effect of cocaine sensitization on mouse immunoreactivity (483) 309
- Kunimoto, S., see Ando, H. (483) 207
- Kuo, R.-Y., see Wu, C.-C. (483) 187
- Langer, T., see Spetea, M. (483) 301
- Lasoń, W., see Kubera, M. (483) 309
- Li, J., see Chen, C. (483) 175
- Lin, C.-L., see Chen, Y.-C. (483) 215
- Liu-Chen, L.-Y., see Chen, C. (483) 175
- López-Muñoz, F.J., see Diaz-Reval, M.I. (483) 241
- Maeno, K., see Kimura, Y. (483) 37
- Maes, M., see Kubera, M. (483) 309
- Maffia, P., see Cuzzocrea, S. (483) 79
- Magnarin, M., Morelli, M., Rosati, A., Bartoli, F., Candussio, L., Giralardi, T. and Decorti, G.  
Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK<sub>1</sub> cells (483) 19
- Maksay, G., Bíró, T. and Kiss, B.  
Vinbustine decelerates [<sup>3</sup>H]N-methylscopolamine binding to recombinant human muscarinic M<sub>1</sub>–M<sub>4</sub> acetylcholine receptors (483) 229
- Marchese, G., Bartholini, F., Rui, S., Casti, P., Casu, G.L. and Pani, L.  
Ritanserin counteracts both rat vacuolar chewing movements and nigrostriatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol (483) 65
- Margaill, I., see Paucard, A. (483) 259
- Marsh, S.J., see Narenjkar, J. (483) 95
- Marsh, M. and Moore, P.K.  
Effect of nitric oxide releasing paracetamol and flurbiprofen on cytokine production in human blood (483) 317
- Matsumoto, K., see Ando, H. (483) 207
- Meurs, H., see Gosens, R. (483) 71
- Mitamura, M., see Ogura, J. (483) 139
- Moore, P.K., see Marshall, M. (483) 317
- Morelli, M., see Magnarin, M. (483) 19
- Mosbacher, J., see Urwyler, S. (483) 147
- Mugishima, H., see Ando, H. (483) 207
- Murayama, T., see Ogura, J. (483) 139
- Myhrer, T., Enger, S. and Aas, P.  
Cognitive side effects in rats caused by pharmacological agents used to prevent soman-induced lethality (483) 271
- Naitou, Y., see Kimura, Y. (483) 37
- Nakazawa, K., Ojima, H., Ishii-Nozawa, R., Takeuchi, K. and Ohno, Y.  
Amino acid substitutions from an indispensable disulfide bond affect P2X<sub>2</sub> receptor activation (483) 29
- Narenjkar, J., Marsh, S.J. and Assem, E.-S.K.  
Inhibition of the antigen-induced activation of RBL-2H3 cells by charybdotoxin and cetiedil (483) 95
- Narenjkar, J., Assem, E.-S.K. and Ganellin, C.R.  
Inhibition of the antigen-induced activation of RBL-2H3 cells by cetiedil and some of its analogues (483) 107
- Narikawa, S., see Takeda, M. (483) 133
- Nelemans, S.A., see Gosens, R. (483) 71
- Neuhaus, T., Pabst, S., Stier, S., Weber, A.-A., Schrör, K., Sachinidis, A., Vetter, H. and Ko, Y.D.  
Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate (483) 223
- Norman, A.B., Buesing, W.R., Norman, M.K., Tabet, M.R. and Tsibulsky, V.L.  
The self-administration of WIN 35,428 and cocaine: comparisons of satiety threshold and elimination half-life in rats (483) 281
- Norman, M.K., see Norman, A.B. (483) 281
- Noshiro, R., see Takeda, M. (483) 133
- Nowak, E., see Kubera, M. (483) 309
- Ogura, J., Mitamura, M., Someya, A., Shimamura, K., Takayama, H., Aimi, N., Horie, S. and Murayama, T.  
Mesaconitine-induced relaxation in rat aorta: role of Na<sup>+</sup>/Ca<sup>2+</sup> exchangers in endothelial cells (483) 139
- Ohno, Y., see Nakazawa, K. (483) 29
- Ojima, H., see Nakazawa, K. (483) 29
- Oliva, P., see Sepúlveda, J. (483) 249
- Onozato, M.L., see Takeda, M. (483) 133
- Pabst, S., see Neuhaus, T. (483) 223
- Palmier, B., see Paucard, A. (483) 259
- Pani, L., see Marchese, G. (483) 65
- Patel, N.S.A., see Cuzzocrea, S. (483) 79
- Paucard, A., Palmier, B., Croci, N., Taillieu, F., Plotkine, M. and Margaill, I.  
Biphasic modulation by nitric oxide of caspase activation due to malonate injection in rat striatum (483) 259
- Piao, F.L., Cao, C., Han, J.H., Kim, S.Z. and Kim, S.H.  
Calcitonin gene-related peptide-induced suppression of atrial natriuretic peptide release through receptors for CGRP<sub>1</sub> but not for calcitonin and amylin (483) 295
- Pisano, B., see Cuzzocrea, S. (483) 79
- Plotkine, M., see Paucard, A. (483) 259
- Postnikov, A.B., see Severina, I.S. (483) 127
- Pozza, M.F., see Urwyler, S. (483) 147
- Preobrazhenskaya, M.N., see Severina, I.S. (483) 127
- Pyatakova, N.V., see Severina, I.S. (483) 127

- Raffa, R.B., Stagliano, G.W. and Spencer, S.D.  
Protonation effect on drug affinity (483) 323
- Riba, P., see Spetea, M. (483) 301
- Rogers, T.J., see Chen, C. (483) 175
- Rosati, A., see Magnarin, M. (483) 19
- Ruffels, J., Griffin, M. and Dickenson, J.M.  
Activation of ERK1/2, JNK and PKB by hydrogen peroxide in human SH-SY5Y neuroblastoma cells: role of ERK1/2 in H<sub>2</sub>O<sub>2</sub>-induced cell death (483) 163
- Ruii, S., see Marchese, G. (483) 65
- Sachinidis, A., see Neuhaus, T. (483) 223
- Saito, S., see Ando, H. (483) 207
- Schaafsma, D., see Gosens, R. (483) 71
- Schmidhammer, H., see Spetea, M. (483) 301
- Schreiber, R., see De Vry, J. (483) 55
- Schrör, K., see Neuhaus, T. (483) 223
- Schütz, J., see Spetea, M. (483) 301
- Scott, V.E., Davis-Taber, R.A., Silvia, C., Hoogenboom, L., Choi, W., Kroeger, P., Whiteaker, K.L. and Gopalakrishnan, M.  
Characterization of human urinary bladder K<sub>ATP</sub> channels containing SUR2B splice variants expressed in L-cells (483) 195
- Sepúlveda, J., Oliva, P. and Contreras, E.  
Neurochemical changes of the extracellular concentrations of glutamate and aspartate in the nucleus accumbens of rats after chronic administration of morphine (483) 249
- Sevak, R.J., France, C.P. and Koek, W.  
Neuroleptic-like effects of  $\gamma$ -hydroxybutyrate: interactions with haloperidol and dizocilpine (483) 289
- Severina, I.S., Pyatakova, N.V., Postnikov, A.B., Preobrazhenskaya, M.N. and Khropov, Y.V.  
Antitumor antibiotic streptonigrin and its derivatives as inhibitors of nitric oxide-dependent activation of soluble guanylyl cyclase (483) 127
- Shimada, I., see Kimura, Y. (483) 37
- Shimamura, K., see Ogura, J. (483) 139
- Silvia, C., see Scott, V.E. (483) 195
- Siwanowicz, J., see Kubera, M. (483) 309
- Someya, A., see Ogura, J. (483) 139
- Spencer, S.D., see Raffa, R.B. (483) 323
- Spetea, M., Friedmann, T., Riba, P., Schütz, J., Wunder, G., Langer, T., Schmidhammer, H. and Fürst, S.  
In vitro opioid activity profiles of 6-amino acid substituted derivatives of 14-*O*-methyloxymorphone (483) 301
- Stagliano, G.W., see Raffa, R.B. (483) 323
- Stier, S., see Neuhaus, T. (483) 223
- Szabo, I., see Chen, C. (483) 175
- Tabet, M.R., see Norman, A.B. (483) 281
- Tai, C.-T., see Chen, Y.-C. (483) 215
- Taillieu, F., see Paucard, A. (483) 259
- Takayama, H., see Ogura, J. (483) 139
- Takeda, M., Noshiro, R., Onozato, M.L., Tojo, A., Hasannejad, H., Huang, X.-L., Narikawa, S. and Endou, H.  
Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors (483) 133
- Takeuchi, K., see Nakazawa, K. (483) 29
- Tatsuo, M.A.K.F., see da Motta, P.G. (483) 233
- Terrón, J.A., see Díaz-Reval, M.I. (483) 241
- Thiemermann, C., see Cuzzocrea, S. (483) 79
- Tojo, A., see Takeda, M. (483) 133
- Tottori, K., see Jordan, S. (483) 45
- Tsang, S.Y., Yao, X., Wong, C.M., Chan, F.L., Chen, Z.-Y. and Huang, Y.  
Differential regulation of K<sup>+</sup> and Ca<sup>2+</sup> channel gene expression by chronic treatment with estrogen and tamoxifen in rat aorta (483) 155
- Tsibulsky, V.L., see Norman, A.B. (483) 281
- Urwyler, S., Gjoni, T., Kaupmann, K., Pozza, M.F. and Mosbacher, J.  
Selected amino acids, dipeptides and arylalkylamine derivatives do not act as allosteric modulators at GABA<sub>B</sub> receptors (483) 147
- Veiga, A.P.C., see da Motta, P.G. (483) 233
- Ventura-Martínez, R., see Díaz-Reval, M.I. (483) 241
- Vetter, H., see Neuhaus, T. (483) 223
- Wang, W.-Y., see Wu, C.-C. (483) 187
- Wanibuchi, F., see Kimura, Y. (483) 37
- Weber, A.-A., see Neuhaus, T. (483) 223
- Whiteaker, K.L., see Scott, V.E. (483) 195
- Wong, C.M., see Tsang, S.Y. (483) 155
- Wu, C.-C., Wang, W.-Y., Kuo, R.-Y., Chang, F.-R. and Wu, Y.-C.  
Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases (483) 187
- Wu, Y.-C., see Wu, C.-C. (483) 187
- Wunder, G., see Spetea, M. (483) 301
- Yamaguchi, T., see Kimura, Y. (483) 37
- Yao, X., see Tsang, S.Y. (483) 155
- Yokoyama, S.-i., see Ando, H. (483) 207
- Zaagsma, J., see Gosens, R. (483) 71
- Zajicova, A., see Kubera, M. (483) 309